From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.
about
Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnosticsMechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and TestingKinomic profiling of electromagnetic navigational bronchoscopy specimens: a new approach for personalized medicineMolecular pathology of lung cancer: current status and future directionsCurrent concepts on the molecular pathology of non-small cell lung carcinoma.The evolving genomic classification of lung cancer.Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel.Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.mRNA and microRNA expression profiles of radioresistant NCI-H520 non-small cell lung cancer cells.Reliably Detecting Clinically Important Variants Requires Both Combined Variant Calls and Optimized Filtering Strategies.Validation and Application of a Custom-Designed Targeted Next-Generation Sequencing Panel for the Diagnostic Mutational Profiling of Solid Tumors.Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment responseTowards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs.Current and future molecular diagnostics in non-small-cell lung cancer.TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.Lung Cancer Biomarkers.Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer.Integrative analysis for the discovery of lung cancer serological markers and validation by MRM-MS.Genome-wide functional analysis on the molecular mechanism of specifically biosynthesized fluorescence Eu complex.Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung.Challenges and opportunities for next-generation sequencing in companion diagnostics.Nicotinamide N-methyltransferase in non-small cell lung cancer: promising results for targeted anti-cancer therapy.Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer.Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?[New development lines in immunology. Perspective of pathology].Imaging of molecular target modulation in oncology: challenges of early clinical trials
P2860
Q26864332-936EA0CE-0EE8-4847-B099-5354B2061E67Q28077785-61784DCB-CAAF-48B2-B91A-79819D545927Q28542940-5F7D1EC6-0BBD-4D41-8008-726B66195350Q34194997-1CE1D00D-28E8-44B3-A738-4A2398887AAFQ34310062-3A02C392-DCA3-4307-AC74-3AAEB8D0F0BDQ34852043-EDBAC4E1-E354-45FD-B0F4-B52AA43F0FBAQ35043965-79ECB9BA-2BEB-4461-9EF3-7392E663EB55Q35345489-71120BD0-9A53-4369-96C9-BECB6EC54060Q35728606-733BE156-BB1E-4FFD-8FB7-272DD844A0C6Q35850909-73762144-F63F-4A99-8704-3ED902CD1F4CQ35996102-D3060500-C45D-486E-AAC4-6140A3342BC9Q36207381-E21AC05D-4EA5-42CF-B0A0-BD96AB683EB0Q36264188-5BF953B9-1E28-4B70-89AA-6DFFC8C8C418Q38213830-92F679B3-B753-4F26-B5DB-2A629206C192Q38513661-0DEDDA4B-D77E-41E6-BE9C-78A00C74CBE3Q38543780-69737083-DBAB-4376-B0EE-31DC8700409AQ38853578-A3C35E4D-21B2-42D5-964D-10B0F53B0690Q39002233-1E7C5471-8D21-41B4-A8A7-55349E9EE30EQ39027394-9BEC609F-1C06-4C1E-93BC-456A25930299Q40202162-E8ED5CC7-F21B-4341-93D2-AFB412448BBCQ41063959-39D65FF5-DFD1-445E-886A-8C4E69C497CEQ41513462-74170612-85ED-489F-9ED3-E30F1460C824Q42654016-64AF12BC-FE07-4533-A1F0-057DF46116E1Q43542635-E8FD8E0C-D5C2-46FC-BA64-A82DD6029A03Q43561078-ECD9FCF9-5E18-44C2-9366-9BE1DEF9A81CQ43891611-4B1C126B-F5E3-401A-AD87-1F4116714230Q44201011-FC3E7ED7-3FB9-469F-8552-287DE493FEBEQ51139197-5414727D-64C0-4990-8E2C-BB3DAB6C3565Q52904961-50ADB7A5-D35C-43B2-A967-BB9872331E42Q53088478-4ABA8414-52DA-4CDE-8A8E-046465690D53Q54397306-DD097A6C-382F-4D25-9162-DCF2EAD4CAE5Q57758791-715E4429-9938-4945-874A-1895229DDBA4
P2860
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
From targets to targeted thera ...... non-small cell lung carcinoma.
@ast
From targets to targeted thera ...... non-small cell lung carcinoma.
@en
type
label
From targets to targeted thera ...... non-small cell lung carcinoma.
@ast
From targets to targeted thera ...... non-small cell lung carcinoma.
@en
prefLabel
From targets to targeted thera ...... non-small cell lung carcinoma.
@ast
From targets to targeted thera ...... non-small cell lung carcinoma.
@en
P2093
P2860
P356
P1433
P1476
From targets to targeted thera ...... non-small cell lung carcinoma
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDS478
P577
2012-11-06T00:00:00Z